Who can join
Studies for children and teens
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
468 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Birmingham, AL + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Scottsdale, AZ + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Scottsdale, AZ + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 1/Phase 2
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
JCR Pharmaceuticals Co., Ltd.
- Location
- Oakland, CA
- Eligibility basics
- Up to age 5
- RecruitingPhase 3
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
AstraZeneca
- Location
- Aurora, CO + 1 other US site
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
Optinose US Inc.
- Location
- Orange, CA + 18 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old
Neurocrine Switzerland GmbH
- Location
- San Francisco, CA + 10 other US sites
- Eligibility basics
- Ages 4 mo–3
- RecruitingPhase 3
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active…
AbbVie
- Location
- Phoenix, AZ + 4 other US sites
- Eligibility basics
- Ages 1–17
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Huntsville, AL + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Incyte Corporation
- Location
- Birmingham, AL + 65 other US sites
- Eligibility basics
- Ages 2–11
- Recruiting
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
Starlight Cardiovascular Inc
- Location
- Los Angeles, CA + 7 other US sites
- Eligibility basics
- Up to age 6 mo
- Recruiting
GAINS Expert Guiding Technology to Coach Life Skill Teaching
Guiding Technologies Corporation
- Location
- Fayetteville, AR
- Eligibility basics
- Ages 3–10
- RecruitingPhase 2
Study of Resmetirom in Children and Adolescents With MASH
Madrigal Pharmaceuticals, Inc.
- Location
- Indianapolis, IN
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Bristol-Myers Squibb
- Location
- Sacramento, CA + 4 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
Takeda
- Location
- Birmingham, AL + 9 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 3
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
Takeda
- Location
- Chula Vista, CA + 10 other US sites
- Eligibility basics
- Ages 4–17
- RecruitingPhase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Eli Lilly and Company
- Location
- Birmingham, AL + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 1/Phase 2
Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy
Ferring Pharmaceuticals
- Location
- Mobile, AL + 3 other US sites
- Eligibility basics
- Ages 1–8
- RecruitingPhase 1/Phase 2
JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency
Jaguar Gene Therapy, LLC
- Location
- Chicago, IL + 2 other US sites
- Eligibility basics
- Ages 2–9
- RecruitingPhase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Bristol-Myers Squibb
- Location
- Fremont, CA + 26 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 1/Phase 2
Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators
Astellas Gene Therapies
- Location
- Chicago, IL + 3 other US sites
- Eligibility basics
- Up to age 3 · Men only
- RecruitingPhase 1/Phase 2
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Ionis Pharmaceuticals, Inc.
- Location
- Ann Arbor, MI + 4 other US sites
- Eligibility basics
- Ages 2–12
- RecruitingPhase 3
Donidalorsen Treatment in Children With Hereditary Angioedema
Ionis Pharmaceuticals, Inc.
- Location
- Santa Monica, CA + 7 other US sites
- Eligibility basics
- Ages 2–11
- RecruitingPhase 3
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
AbbVie
- Location
- Little Rock, AR + 11 other US sites
- Eligibility basics
- Ages 5–17
Questions
If I fit this group, will I qualify?
Not necessarily. Age and sex limits are only the first filter. Each study has its own inclusion and exclusion criteria, and the research team decides at screening.
Where do these age and sex limits come from?
From the eligibility section of each study’s official ClinicalTrials.gov record. We don’t infer eligibility from anything else.